Full Transcript
Access the complete word-for-word transcript for easy reference and accessibility.
Beware of these four regulations and standards before using AI in pharma manufacturing. As AI adoption accelerates across pharmaceutical manufacturing, the potential for faster batch releases and higher yields comes with risks such as black box decision making, model drift, and compliance breaches.
In a highly regulated environment, deploying AI without a solid regulatory foundation can quickly lead to costly recalls or FDA warning letters. To harness AI safely and effectively, pharma manufacturers must navigate four critical standards and regulatory frameworks that define compliant AI today.
To harness AI safely and effectively, pharma manufacturers must navigate four critical standards and regulatory frameworks that define compliant AI today. 1. FDA’s Existing CGMP Regulations. Existing CGMP regulations apply to AI-generated outputs without exception.
Rather than creating entirely new laws, the FDA uses established rules like 21 CFR, Parts 210 and 211 to hold AI systems accountable. Under their latest framework, the rigour required for your AI model depends heavily on its specific context of use and its level of influence on regulatory decisions.
Under their latest framework, the rigour required for your AI model depends heavily on its specific context of use and its level of influence on regulatory decisions. Meaning, the greater the AI’s impact on product quality or safety, the higher the burden of credibility and validation you must prove.
2. EU’s Annex 22 and the Static vs. Probabilistic Distinction. The EU draws a strict line under Annex 22, its dedicated GMP draft for AI. It divides systems into two clear categories—static, deterministic models that produce fixed outputs from identical inputs…
…and adaptive, probabilistic models that evolve with new data, including most Gen-AI and LLMs. Under Annex 22, only static models are allowed in critical GMP operations that impact product quality or purity, excluding adaptive AI from core manufacturing decisions by design.
Under Annex 22, only static models are allowed in critical GMP operations that impact product quality or purity, excluding adaptive AI from core manufacturing decisions by design. 3. The FDA-EMA Joint Position 10 Principles for Convergence.
3. The FDA-EMA Joint Position 10 Principles for Convergence. The FDA and EMA jointly issued 10 guiding principles for good AI practise, establishing a shared global blueprint for compliant AI across the entire product lifecycle.
While non-binding for now, these principles signal where future binding laws are headed, focussing heavily on human-centric oversight, risk-proportional validation, transparency, and data governance to ensure international regulatory harmony.
4. The Standards Body Layer. Finally, industry standards turn high-level regulatory expectations into practical execution. The ISPA-GAMP AI Guide provides the actionable blueprint for validating AI-enabled GXP systems across their lifecycle…
…while ISO-IEC 42001 serves as the overarching auditable AI management system. Together, these frameworks help pharma manufacturers solve a growing structural challenge, managing regulatory liability in-house while operating complex AI tools built by external suppliers and tech partners.
Together, these frameworks help pharma manufacturers solve a growing structural challenge, managing regulatory liability in-house while operating complex AI tools built by external suppliers and tech partners. Are you concerned your AI might be a regulatory risk?
/ ANY QUESTIONS? WE'D LOVE TO HELP
Frequently Asked Questions
Mareana has helped numerous firms in the Pharmaceutical, Chemical, Medical Device, and Industrial Manufacturing industries.
AI used in pharmaceutical manufacturing is subject to existing pharmaceutical regulations, including the FDA’s Current Good Manufacturing Practice (CGMP) requirements under 21 CFR Parts 210 and 211. The regulatory expectations depend on the AI system’s context of use and how significantly it influences product quality, safety, or regulatory decisions.
The FDA currently applies existing CGMP regulations to AI-generated outputs rather than relying solely on separate AI-specific regulations. Pharmaceutical manufacturers remain responsible for ensuring that AI systems and their outputs are appropriately controlled, validated, and suitable for their intended use.
EU GMP Annex 22 is a draft framework addressing the use of artificial intelligence in pharmaceutical manufacturing. It distinguishes between static, deterministic AI models and adaptive, probabilistic models, with particular attention to their use in GMP-critical operations.
Under the draft EU Annex 22 approach, adaptive or probabilistic AI is restricted from critical GMP operations that directly affect product quality or purity. This makes the distinction between static and adaptive AI particularly important when determining whether an AI application is suitable for a regulated manufacturing process.
The FDA and EMA have jointly published 10 guiding principles for good AI practice covering AI use throughout the pharmaceutical product lifecycle. The principles emphasize human-centric oversight, risk-proportional validation, transparency, and data governance. Although currently non-binding, they indicate the direction of international regulatory convergence for AI.
The ISPE GAMP AI Guide provides practical guidance for validating AI-enabled GxP systems across their lifecycle, while ISO/IEC 42001 provides a broader framework for establishing an auditable AI management system. Together, these standards can help pharmaceutical manufacturers translate high-level regulatory expectations into practical AI governance, validation, and lifecycle controls.
Contact Us
Would you like to learn more about our pharmaceutical manufacturing solutions? Fill out the form below and one of our experts will reach out to you promptly.